Work

Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors.

Year: 2016
Type: article
Abstract: Alirocumab (Praluent): first in the new class of PCSK9 inhibitors.
Source: PubMed
Authors: Marina Manniello, Michele Pisano
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2413208148
FWCI: 0.996
Cites: 8
Cited by: 40
Related to: 10